What's new in paediatric SLE?

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 5, 2009, Pages 699-708

  von Scheven, Emily ^a   Bakkaloglu, Aysin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

atherosclerosis; childhood; nephritis; outcome; paediatric; Systemic Lupus Erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; ATACICEPT; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; LIVE VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; PROGESTERONE; RAPAMYCIN; RITUXIMAB; STEROID; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; CONTRACEPTION; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EXERCISE; GASTROINTESTINAL SYMPTOM; GONADAL DISEASE; HEART MUSCLE ISCHEMIA; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNIZATION; INFECTION; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MORTALITY; ONSET AGE; OUTCOMES RESEARCH; PATHOGENESIS; PATIENT SAFETY; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK REDUCTION; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; CHILD; CHILD, PRESCHOOL; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MYOCARDIAL ISCHEMIA; PEDIATRICS; SURVIVAL RATE; YOUNG ADULT;

EID: 71749106517     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.07.008     Document Type: Review

References (46)

1. Petty R., and Laxer R. Systemic lupus erythematosus. In: Cassidy J., and Petty R. (Eds). Textbook of pediatric rheumatology. 5th edn. (2005), WB Saunders, Co., Philadelphia 342-385
2. Tucker L.B., Menon S., Schaller J.G., and Isenberg D.A. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 34 9 (1995) 866-872
3. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54 8 (2006) 2550-2557
4. Ravelli A., Ruperto N., and Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 17 5 (2005) 568-573
5. Bakkaloglu A. Lupus nephropathy in children. Nephrol Dial Transplant 16 Suppl. 6 (2001) 126-128
6. Appel G., and D'aqati V. Renal involvement in multisystem diseases. Part I: lupus nephritis. In: Massrey S., and Glassock R. (Eds). Textbook of nephrology. 4th edn. (2001), Lippincott Williams & Wilkins, Philadelphia 777-781
7. Mavragani C.P., and Moutsopoulos H.M. Lupus nephritis: current issues. Ann Rheum Dis 62 9 (2003) 795-798
8. Bertsias G.K., Nakou M., Choulaki C., et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 60 1 (2009) 207-218
9. Cameron J.S. Lupus and lupus nephritis in children. Adv Nephrol Necker Hosp 22 (1993) 59-119
10. Gordon C., Jayne D., Pusey C., et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18 3 (2009) 257-263
11. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 2 (2004) 241-250
12. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol 14 2 (2000) 158-166
13. Marks S., and Tullus K. Lupus nephritis. In: Geary D., and Schaefer F. (Eds). Comprehensive pediatric nephrology. 1st edn. (2008), Elsevier, Philadelphia 329-342
14. Marks S.D., Sebire N.J., Pilkington C., and Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol 22 1 (2007) 77-83
15. Austin III H.A., Boumpas D.T., Vaughan E.M., and Balow J.E. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10 9 (1995) 1620-1628
16. Faurschou M., Starklint H., Halberg P., and Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 33 8 (2006) 1563-1569
17. Gamba G., Quintanilla L., del Bosque M.D., Chew-Wong A., and Correa-Rotter R. Clinical course and prognostic factors in lupus nephropathy. Rev Invest Clin 52 4 (2000) 397-405
18. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 8 (2002) 2121-2131
19. Bansal V.K., and Beto J.A. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 29 2 (1997) 193-199
20. Sinclair A., Appel G., Dooley M.A., et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16 12 (2007) 972-980
21. Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D., and Lachin J.M. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326 21 (1992) 1373-1379
22. Wright E.C., Tullus K., and Dillon M.J. Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol 19 10 (2004) 1108-1114
23. Marks S.D., Patey S., Brogan P.A., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 10 (2005) 3168-3174
24. Masood S., Jayne D., and Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus 18 2 (2009) 106-115
25. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350 10 (2004) 971-980
26. Siso A., Ramos-Casals M., Bove A., et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17 4 (2008) 281-288
27. Bjornadal L., Yin L., Granath F., Klareskog L., and Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 31 4 (2004) 713-719
28. Fischer L.M., Schlienger R.G., Matter C., Jick H., and Meier C.R. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93 2 (2004) 198-200
29. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 5 (1997) 408-415
30. Hersh A.O., von Scheven E., Yazdany J., et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 61 1 (2009) 13-20
31. Berenson G.S., Wattigney W.A., Tracy R.E., et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 70 9 (1992) 851-858
32. Falaschi F., Ravelli A., Martignoni A., et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43 6 (2000) 1405-1409
33. Ilowite N.T., Samuel P., Ginzler E., and Jacobson M.S. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31 7 (1988) 859-863
34. Posadas-Romero C., Torres-Tamayo M., Zamora-Gonzalez J., et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 50 1 (2004) 160-165
35. Sarkissian T., Beyenne J., Feldman B., Adeli K., and Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 54 4 (2006) 1283-1290
36. Soep J.B., Mietus-Snyder M., Malloy M.J., Witztum J.L., and von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 51 3 (2004) 451-457
37. Svenungsson E., Gunnarsson I., Fei G.Z., et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48 9 (2003) 2533-2540
38. Hayata A.L., Borba E.F., Bonfa E., Kochen J.A., and Goldenstein-Schainberg C. The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus. Lupus 14 8 (2005) 613-617
39. Ilowite N.T., Copperman N., Leicht T., Kwong T., and Jacobson M.S. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22 7 (1995) 1347-1351
40. Camejo G., Olofsson S.O., Lopez F., Carlsson P., and Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis 8 4 (1988) 368-377
41. McMahon M., and Hahn B.H. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19 6 (2007) 633-639
42. Navab M., Berliner J.A., Watson A.D., et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16 7 (1996) 831-842
43. Fernandes J.L., Mamoni R.L., Orford J.L., et al. Increased Th1 activity in patients with coronary artery disease. Cytokines 26 3 (2004) 131-137
44. Thompson T., Sutton-Tyrrell K., Wildman R.P., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58 3 (2008) 835-842
45. Houghton K.M., Tucker L.B., Potts J.E., and McKenzie D.C. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum 59 4 (2008) 537-545
46. Schanberg L.E., Sandborg C., Barnhart H.X., et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 60 5 (2009) 1496-1507